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Abstract
Baron and Kenny (1986, 82,339 Google Scholar citations) proposed es-
timators of direct and indirect effects: the part of a treatment effect that
is mediated by a covariate and the part that is not. Subsequent work on
natural direct and indirect effects provides a formal causal interpretation.
Natural direct and indirect effects use cross-worlds counterfactuals: out-
comes under treatment with the mediator “set” to its value without treat-
ment. Organic direct and indirect effects (Lok 2016) avoid cross-worlds
counterfactuals, using “organic” interventions on the mediator while keep-
ing the initial treatment fixed at “treatment”. Organic direct and indirect
effects apply also to settings where the mediator cannot be “set”. In lin-
ear models where there is no treatment-mediator interaction, both organic
and natural indirect effects lead to the same estimators as in Baron and
Kenny (1986). In this article, I propose organic interventions on the me-
diator that keep the initial treatment fixed at “no treatment”, leading
to an alternative version of organic direct and indirect effects. I show
that the product method, proposed in Baron and Kenny (1986), holds
in linear models for these new direct and indirect effects even if there is
treatment-mediator interaction. Furthermore, I argue that this alterna-
tive organic indirect effect is more relevant for drug development than
the traditional natural or organic indirect effect. We illustrate the impor-
tance of organic indirect effects by estimating the organic indirect effect
of curative HIV treatments mediated by two HIV persistence measures,
using ART interruption data without curative HIV treatments combined
with an estimated/hypothesized effect of the curative HIV treatments on
on-ART HIV persistence measures.
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1 Introduction: direct and indirect effects
Direct and indirect effects decompose the effect of a treatment A on outcome Y
into:
• a part that is mediated through covariate M (the indirect effect)
• a part that is not (the direct effect).
For example, treatment A could be a blood pressure lowering medication, and
the outcome Y could be whether a person had a heart attack. The mediation
question could then be: How much of the effect of the blood pressure lowering
medication is mediated by its effect on blood pressure, and how much (if any)
by other pathways? Another mediation question is (Lok (2016)): How much of
the effect of the effect of antidepressants on depressive symptoms is mediated
through participants’ expectations? Another example is in HIV research. New
HIV curative drugs are being developed to reduce HIV persistence while patients
are on antiretroviral therapy (ART). The clinical effects of such therapies are
assessed by ART withdrawal in the study participants to identify viral control
off-ART. The mediation question (see Section HIV) is: what is the effect of an
HIV curative drug on ART-free viral control mediated by the drug’s effect on the
HIV persistence, as measured on-ART by e.g. single-copy plasma HIV-RNA?
The seminal article on the topic of mediation analysis, Baron and Kenny
(1986), has over 80,000 citations in Google Scholar, many of them from the
last 10 years. Mediation analysis is especially important in the health sci-
ences, like epidemiology and psychology. Knowing the type of assumptions
under which these analyses are valid is paramount. Such assumptions are not
yet well-established. From Robins and Richardson (2011): “The nature of the
relationship between the sentence expressing these causal conclusions and the
statistical computer calculations performed on the strings of numbers has been
obscure.”
One of the disadvantages of many current causal interpretations of medi-
ation analysis (see e.g. Pearl (2001), Imai et al. (2010), VanderWeele (2009),
and Tchetgen-Tchetgen (2011)) lies in their reliance on quantities such as: the
outcome under treatment but with the mediator “set” to its value without
treatment. These are called cross-world counterfactuals, since they rely on two
simultaneous but different situations/worlds, “treatment” and “no treatment”,
which never occur concurrently. Then, obviously, the identifying assumptions
are also cross-world assumptions, and these have often been disputed (Robins
and Richardson (2011)), and have led some researchers to entirely forego causal
mediation analysis.
Lok (2016) has proposed an approach to causal mediation analysis that does
not rely on cross-worlds quantities or cross-world assumptions. This approach,
organic direct and indirect effects, is outlined in Section 3. This article proposes
to adapt organic direct and indirect effects further, and proposes direct and
indirect effects that are
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• Closer to the original approach to mediation analysis by Baron and Kenny
(1986), and
• More useful in identifying the indirect effect of treatments in the pre-
clinical stage, to select the most promising treatments for further investi-
gation in randomized trials.
This article thus has three purposes: to bring organic direct and indirect effects
to the attention of epidemiologists amd clinical trialists, to bring causal medi-
ation analysis closer to the original approach in Baron and Kenny (1986), and
to make causal mediation analysis more useful in the selection of treatments for
randomized trials.
2 Setting and notation
We start with the situation where treatment A is randomized. Denote the pre-
treatment common causes of the mediator M and the outcome Y by C. As is
usual in the mediation literature, we start by assuming that there are no post-
treatment common causes of the mediator M and the outcome Y . This can be
relaxed, see Lok (2017). Throughout, the subscript 0 indicates “without treat-
ment” and the subscript 1 indicates “under treatment”. The DAG in Figure 1
illustrates the mediation set-up. Notice the absence of an arrow from C into A
since treatment is randomized.
Figure 1: DAG summarizing the data
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We adopt the usual Consistency Assumption relating the observed data to
the counterfactual data:
Assumption: (Consistency). On A = 1, M = M1 and Y = Y1. On A = 0,
M = M0 and Y = Y0.
3 Definition of causal direct and indirect effects
3.1 Natural direct and indirect effects
Historically (e.g. Pearl (2001), Imai et al. (2010), VanderWeele (2009), Robins
and Richardson (2011) and Tchetgen-Tchetgen (2011)), causal direct and indi-
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rect effects have often been defined in terms of the following counterfactuals: the
outcomes under treatment had the mediator level been “set” to the mediator
level without treatment: Y1,M0 . There are two issues with these counterfactual
outcomes Y1,M0 :
• Under treatment, M0 is not observed. Thus, even if we could set the
mediator, how to set it to M0 under treatment (A = 1)?
• How to set the mediator is usually left unanswered, so the outcomes Y1,M0
are undefined in many practical situations. Cole and Frangakis (2009)
provide an illustrative example: “There are many competing ways to as-
sign (hypothetically) a body mass index of 25 kg/m2 to an individual, and
each of them may have a different causal effect on the outcome”.
Based on the outcomes Y1,M0 , these current causal approaches to mediation
analysis focus on natural direct and indirect effects:
• Natural direct effect: E (Y1,M0 − Y0) (not mediated: M ≡M0).
• Natural indirect effect: E (Y1 − Y1,M0) (mediated through M : M1 vs M0).
To estimate the natural direct and indirect effect, since treatment A is ran-
domized, estimation of EY1 and EY0 is standard. One can focus on estimating
E (Y1,M0). Under (strong!) conditions, with C representing all pre-treatment
common causes of the mediator M and the outcome Y : the “Mediation For-
mula” holds (see e.g. Pearl (2001)):
E (Y1,M0) =∫
(m,c)
E [Y |M = m,C = c, A = 1] fM |C=c,A=0(m)fC(c)dmdc.
This result is obviously appealing: first, the pre-treatment C are measured, then
M follows its distribution under A = 0, and then Y follows its distribution under
A = 1. The conditions under which this was proven were strong, and relied on
cross-worlds assumptions. In addition, most causal mediation approaches need
many counterfactual outcomes: not only Y1,M0 , also all Ya,m: the outcomes
with the treatment set to a and the mediator set to m. Wnen the mediator is
a second medication, such as aspirin in Pearl (2001), these outcomes Ya,m are
conceivable. However, if the mediator is a patient characteristic or covariate, as
is often the case in applications, these outcomes Ya,m are often not conceivable.
Under additional conditions (linear models and no exposure-mediator inter-
action), the resulting estimators are the same as in Baron and Kenny (1986).
Under these conditions, the causal inference literature thus adds a causal inter-
pretation to the estimators from Baron and Kenny (1986).
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3.2 Organic direct and indirect effects: an intervention-
based approach
Lok (2016) has shown that the mediation formula holds under much weaker
assumptions, for quantities that are not cross-world quantities, and without
cross-world assumptions, as follows.
In the following, I will be an intervention on the mediator that does not
affect C (the pre-treatment common causes of the mediator M and the out-
come Y ). M1,I=1 and Y1,I=1 will denote the mediator and the outcome under
treatment and under intervention I on the mediator.
Definition (Lok (2016)): (organic intervention). An intervention I is an
organic intervention with respect to C if
M1,I=1 | C = c ∼ M0 | C = c (1)
and
Y1,I=1 |M1,I=1 = m,C = c ∼ Y1 |M1 = m,C = c, (2)
where ∼ indicates having the same distribution.
Equation (1) says that I “holds the mediator at its distribution under no
treatment”: given C, there is no difference in the distribution of the mediator
under treatment and intervention I and the distribution of the mediator under
no treatment. Equation (2) says that I “has no direct effect on the outcome”:
under treatment, whether mediator = m came about due to I or without I
does not affect a person’s prognosis. Or, “how the mediator came about is
irrelevant”. That is,
P (Y1,I=1 ≤ y |M1,I=1 = m,C = c) = P (Y1 ≤ y |M1 = m,C = c)
for all y.
An example of an “organic” intervention could be the following. A = 1
could be a blood pressure lowering medicine, M a person’s blood pressure, and
Y the subsequent occurrence of a heart attack. The mediation question: does
A = 1 have a direct effect on heart attacks? It could be, e.g., that A = 1
lowers blood pressure by 10, on average, without changing the shape of the
blood pressure distribution. I should then be an intervention, in the treated,
that increases the blood pressure by 10, on average, without changing the shape
of the blood pressure distribution. Then, M1,I=1 ∼ M0. I could be salt in a
dosage dependent on C = c. The effect of salt on heart attacks is believed to
be through its effect on blood pressure (see for example the CDC website,
http://www.cdc.gov/vitalsigns/Sodium/index.html);
thus, one can posit that
Y1,I=1 |M1,I=1 = m,C = c ∼ Y1 |M1 = m,C = c
for this intervention with salt, I. The role of adding in the salt intervention is
as follows:
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• It takes away the effect mediated by the effect of A = 1 on blood pressure.
• It leaves alone the direct effect of A = 1.
Whether an intervention I is organic can (and should) be discussed with
subject matter experts. In the following, we will draw conclusions about the
effect of organic interventions I.
Definition (Lok (2016): (organic direct and indirect effects):
• EY1 − EY1,I=1: organic indirect effect of treatment A based on I.
(Treatment= 1 for both Y1 and Y1,I=1, so mediated).
• EY1,I=1 − EY0: organic direct effect of treatment A based on I. (Me-
diator same distribution for Y1,I=1 and Y0, so not mediated).
Lok (2016) has shown that the organic direct and indirect effects do not depend
on the intervention I, as long as I is organic. Lok (2016) has also shown that if
C has all pre-treatment common causes of the mediator M and the outcome Y ,
the choice of pre-treatment common causes C does not affect the organic direct
and indirect effects; see also Web-appendix D.
Lok (2016) has proven that under the usual conditions to identify natural
direct and indirect effects, organic direct and indirect effects generalize natural
direct and indirect effects. Provided that M1,I=1 = M0 exists, the usual “cross-
worlds” assumption implies that the intervention I that sets the mediator to
M0, M1,I=1 = M0, is organic! This approach also provides a proof of the me-
diation formula for natural direct and indirect effects under conditions that are
somewhat weaker than usual, see Web-appendix E. Lok (2016) has also proven
that the organic direct and indirect effects generalize the direct and indirect
effects proposed by Didelez et al. (2006), which are based on randomizing and
then setting the mediator.
As for natural direct and indirect effects, under randomized treatment, es-
timation of EY0 and EY1 is standard. For E (Y1,I=1), Lok (2016) provides the
mediation formula (see also Section 4) under only the above conditions.
The Mediation Formula thus provides the same identification result as pre-
viously found for the natural direct and indirect effects studied by previous
authors, of note Pearl (2001), VanderWeele (2009), Imai et al. (2010), and
Tchetgen-Tchetgen (2011). The resulting expression is in terms of observable
quantities only. All ingredients can be estimated using standard methods. The
contribution of Lok (2016) to this literature is, that the definition and therefore
the interpretation of direct and indirect effects as well as the conditions under
which estimators for these effects are valid can be considerably relaxed.
This intervention-based approach answers questions about the effect of in-
terventions, and what one might expect from interventions that satisfy certain
conditions.
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4 Organic direct and indirect effects: towards
an alternative definition
Section 3.2 combined organic interventions on the mediator with “treatment”,
that is, with A = 1. That approach follows analogies with natural direct and in-
direct effects. However, the product method from Baron and Kenny (1986) does
not work for these causal estimands in linear models when there is treatment-
mediator interaction in the outcome model; it only works when there is no
treatment-mediator interaction in the outcome model.
In this article, we propose to combine organic interventions on the medi-
ator with “no treatment”, that is, with A = 0. This proposal has important
advantages:
1. The product method from Baron and Kenny (1986) does work for linear
models regardless of whether there is treatment-mediator interaction in
the outcome model.
2. Organic indirect effects can be estimated with:
(a) The distribution of the mediator under treatment and under “no treat-
ment”, and
(b) The relation between the mediator and the outcome under “no treat-
ment”.
This has important advantages for selecting new treatments with promis-
ing indirect effects for clinical trials (!)
In the following, let M0,I=1 and Y0,I=1 be the mediator and the outcome
under no treatment and under intervention I on the mediator. We re-define an
organic intervention on the mediator as follows:
New definition: (new organic intervention). An intervention I is an
organic intervention with respect to C if
M0,I=1 | C = c ∼ M1 | C = c (3)
and
Y0,I=1 |M0,I=1 = m,C = c ∼ Y0 |M0 = m,C = c. (4)
Equation (3) says that I “changes the distribution of the mediator to that
under treatment”: given C, there is no difference in the distribution of the
mediator under intervention I and the distribution of the mediator under treat-
ment. Equation (4) says that I “has no direct effect on the outcome”: whether
mediator= m came about due to I or without I does not affect a person’s prog-
nosis. Or, “how the mediator came about is irrelevant”. (4) can be relaxed
to
E [Y0,I=1 |M0,I=1 = m,C = c] = E [Y0 |M0 = m,C = c] .
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Lok (2016) showed that for an equation such as (4) to make sense, one needs
all pre-treatment common causes of the mediator M and the outcome Y in
C. Without C, the statement “mediator under no treatment equals m” likely
implies a different prognosis under intervention I (M0,I=1) versus without in-
tervention I (M0), because M0 and M0,I=1 may be related in a different way to
C, which we assumed predicts the outcome.
New definition: (new organic direct and indirect effects):
• EY0,I=1 − EY0: organic indirect effect of treatment A based on I.
((Treatment= 0 for both Y0 and Y0,I=1, so mediated)).
• EY1−EY0,I=1: organic direct effect of treatment A based on I. ((Me-
diator same distribution for Y1 and Y0,I=1, so not mediated)).
Combining organic interventions with “no treatment” provides useful informa-
tion on what to expect from an intervention that:
1. Affects the mediator the same way as the treatment does.
2. Has no direct effect on the outcome.
This is arguably more relevant to drug development than the previously defined
causal indirect effects; for an HIV transmission example see Lok (2016) and
Web-appendix C.
Similar to Lok (2016), see Web-appendix A, it follows that the Mediation
Formula holds for organic interventions:
Theorem (Organic direct and indirect effects: the Mediation Formula for ran-
domized data). Under randomized treatment, consistency, the following holds
for an intervention I that is organic with respect to C:
E (Y0,I=1)
=
∫
(m,c)
E [Y |M = m,C = c, A = 0] fM |C=c,A=1(m)fC(c)dmdc.
Note: this Mediation Formula does not depend on the choice of organic inter-
vention I, confirming that the type of organic intervention does not affect the
magnitude of the organic direct and indirect effect.
Under linear models and in the absence of treatment-mediator interaction in
the outcome model, the new definition of organic direct and indirect effects leads
to the same results as in Lok (2016). It can also be shown (see Web-appendix B)
that with the new definition, the product method from Baron and Kenny (1986)
works for linear models regardless of whether there is treatment-mediator in-
teraction in the outcome model. This is in contrast with both Lok (2016) and
previous work on causal mediation analysis, both for natural direct and indi-
rect effects (Pearl (2001), Imai et al. (2010), VanderWeele (2009), Robins and
Richardson (2011) and Tchetgen-Tchetgen (2011)) as for the approach advo-
cated in Didelez et al. (2006).
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4.1 Selecting new treatments with promising indirect ef-
fects for clinical trials
From the Mediation Formula, the new organic indirect effect EY0,I=1 − EY0
equals (for some examples see Web-appendix ??):∫
(m,c)
E [Y |M = m,C = c, A = 0] (fM |C=c,A=1(m)− fM |C=c,A=0(m)) fC(c)dmdc.
(5)
Thus, the organic indirect effect can be estimated with:
(a) The distribution of the mediator under treatment, A = 1, and under “no
treatment”, A = 0.
(b) The expectation of the outcome given the mediator and pre-treatment co-
variates C under “no treatment”, A = 0 (only under A = 0!).
Expanding mediation analysis in this way is of particular interest because it al-
lows estimation of the indirect effect of potential new treatments that are being
developed to affect a mediator (e.g., Frank and Hargreaves (2003)) without mea-
suring the outcomes under the new treatments, because the distribution of the
outcome given the mediator under treatment is not needed. This is important
for treatment development, where there are often many candidate treatments
for which the effects on biomarkers have been conjectured or established. And
outcomes given the mediator under no treatemnt may be available from obser-
vational studies or placebo arms of completed studies of other treatments. It
is however important to note that evaluating this indirect effect is just a first
step in treatment evaluation, because it only estimates the indirect effect. For
this indirect effect to be the total effect, equation (4) would need to hold for
the candidate treatment A taking the role of I, which can only be confirmed by
measuring the outcomes under the candidate treatment. Thus, the candidate
treatments need to be evaluated in a randomized trial, but randomized trials
could be reserved for treatments with the most promising indirect effect.
5 Selecting HIV curative treatments with promis-
ing indirect effects for clinical trials
Now that ART has rendered HIV a chronic disease, a substantial body of HIV
research is focusing on HIV eradication, or cure, aimed at long-term ART-free
HIV remission Margolis et al. (2016). We argue here that for the development
of medications for HIV eradication, estimating the indirect effect of potential
new curative HIV drugs is particularly important.
Trials have been carried out which interrupt the current standard of care,
ART, in HIV-infected study participants, to investigate the effect of on-ART
biomarkers on the time to viral rebound after stopping ART: the time at which
the HIV viral load in the blood of the participants is above a pre-specified level
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(Li et al. (2016)). However, ART interruption trials have to be carried out with
extreme care, because ART interruption carries significant risks (Strategies for
Management of Antiretroviral Therapy (SMART) Study Group et al. (2006), Li
et al. (2015), Li et al. (2016), Julg et al. (2019)). Because there are currently
many new potential curative HIV drugs in the pre-clinical stages, it is advan-
tageous to carry out ART interruption trials for only the most promising ones
(Ghosn and Delaugerre (2015)).
Potential new HIV curative drugs are often targeting one or more HIV dis-
ease markers. Many new potential curative HIV drugs are designed to affect
an on-ART HIV persistence measure, let’s tentatively call it M , which has an
effect on the time to viral rebound, Y . We show that for such a new HIV
curative drug, equation (5) leads to an estimate of its organic indirect effect
mediated by M , by combining the existing data from Li et al. (2016) with an
estimated/hypothesized effect of the HIV curative drug on the on-ART HIV
persistence measure M . In order to estimate the organic indirect effect of
the potential new curative HIV drug, we show that it is not needed that an
ART interruption study be carried out with the new drug; it suffices to esti-
mate/hypothesize its effect on M , and combine with the data from Li et al.
(2016). ART interruption trials are still needed, since (5) only identifies the
indirect effect, whereas the total effect is the sum of the indirect and the direct
effect; however, ART interruption trials can then be reserved for those curative
HIV drugs with a promising organic indirect effect.
Figure 2: DAG summarizing the HIV cure setting
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Figure 2 describes the DAG for this illustrative analysis. We use the data
from completed ACTG trials described in Li et al. (2016): data on > 100
HIV-infected study participants without curative HIV treatments and with
ART interruptions, and the following biomarker measurements: cell-associated
HIVRNA and single-copy plasma HIV-RNA. For the purpose of this illustrative
analysis, we ignore potential post-treatment common causes of the mediator
and the outcome. We illustrate our methods by estimating, combining the data
from Li et al. (2016) with hypothesized effects of potential new curative HIV
treatments on these biomarkers, the indirect effect of potential new curative
HIV treatments that affect these biomarkers. These organic indirect effects of
potential new curative HIV treatments are the effect on viral rebound of a treat-
ment that has the same effect on the targeted biomarker as the potential new
curative HIV treatment, and no direct effect through other pathways.
The outcome variable is the time to viral rebound after ART interruption.
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We categorize this outcome Y as “suppressed (Y = 1)/not suppressed (Y = 0)
by week 8 of ART interruption”. We consider two potential on-ART media-
tors M , both measures of the HIV persistence: cell-associated HIV RNA and
single-copy plasma HIV RNA, both on the log10 scale. Pre-ART viral load is
a measure of the magnitude of viral replication before ART initiation, which
is known to be predictive of the distribution of viral outcomes after stopping
ART (Treasure et al. (2016), Li et al. (2016)) and is also predictive of on-ART
HIV persistence measures (Riddler et al. (2016), Gandhi et al. (201)). In the
absence of information on the pre-ART viral load, the (pre-ART) nadir CD4
count is our surrogate C, and also a potential pre-treatment common cause of
the mediator and the outcome (Li et al. (2016)).
First, we estimate the indirect effect mediated by M¯ , an indicator of whether
or not the mediator is below the assay limit of detection: M¯ = 1 if the HIV
persistence measure is below the assay limit of detection, and M¯ = 0 if the HIV
persistence measure is above the limit of detection. We estimate the indirect
effect of a curative HIV drug A that increases the odds of M being below the
limit of detection by a factor 2 (given C). The organic indirect effect of the
HIV curative drug mediated by the binary on-ART HIV persistence measure M¯
follows from equation (5):∫
c
P
(
Y = 1|M¯ = 1, C = c, A = 0)P (M¯1 = 1|C = c)fC(c)dc
+
∫
c
P
(
Y = 1|M¯ = 0, C = c, A = 0)P (M¯1 = 0|C = c)fC(c)dc− P (Y0 = 1) .
(6)
Direct calculation (see Web-appendix G) shows that if p0(c) = P (M¯0 = 1|C = c)
and treatment increases the odds by 2, then P (M¯1 = 1|C = c) = 2p0(c)/(1 +
p0(c)). p0(c) can be estimated from the Li et al. (2016) data: the on-ART HIV
persistence data M¯0 and the nadir CD4 data C. We fit a logistic regression
model
logit P (M¯0|C) = η0 + η1C. (7)
P (M¯1 = 1|C = c) is then estimated by p1,ηˆ(c) = 2p0,ηˆ(c)/(1 + p0,ηˆ(c)). To
estimate the organic indirect effect (6), we also fit a logistic regression model
for the probability of virologic control at week 8 of ART interruption given M¯
and C, using the Li et al. (2016) data (Yi, M¯i, Ci), i = 1, . . . , n, without HIV
curative drug (A = 0):
logitpα;m,c = logitP
(
Yi = 1|M¯i = m,Ci = c, Ai = 0
)
= α0 + α1m+ α2c. (8)
The indirect effect (6) mediated by the binary HIV persistence measure M¯ can
then be estimated from the ART interruption data under no curative HIV drug
by
1
n
1∑
m=0
n∑
i=1
pαˆ
(
Y = 1|M¯ = m,C = ci, A = 0
)
Pηˆ(M¯1 = m|C = ci)− 1
n
n∑
i=1
yi,
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that is,
1
n
n∑
i=1
pαˆ;1,ci2p0,ηˆ(ci)/(1+p0,ηˆ(ci))+pαˆ;0,ci(1−p0,ηˆ(ci))/(1+p0,ηˆ(ci))−
1
n
n∑
i=1
yi.
After we have analyzed the data, Table 1 will provide the results of this analysis.
We now return to the original HIV persistence measure, M . We estimate
the organic indirect effect of a new curative HIV drug A, that is, the effect of
a new curative HIV drug without a direct effect, that shifts the distribution of
the mediator M by one log10 given C:
M1 ∼M0 − 1 log10 | C : (9)
the distribution of M1 is the same as the distribution of M0 − 1 log10, given
C. It is imporant to note that this is a shift in the distribution of the mediator
rather than a shift of the actual values (no “rank preservation”), and it is equally
important to note that we can estimate the distribution of M1 under this shift
by subtracting 1 log10 from the mediator M0 under no curative HIV drug. For
M the single-copy plasma HIV RNA, which has a limit of detection of 1, if the
HIV RNA under no curative treatment is less than 10, that translates to an
HIV RNA under the curative treatment of < 1, or below the limit of detection.
The organic indirect effect of a curative HIV treatment A that shifts the
distribution of the mediator by 1 log10 given C equals∫
(m,c)
P (Y = 1|M = m,C = c, A = 0) fM |C=c,A=1(m)fC(c)dmdc− P (Y0 = 1)
=
∫
(m,c)
P (Y = 1|M = m,C = c, A = 0) fM |C=c,A=0(m− 1 log10)fC(c)dmdc
−P (Y0 = 1)
=
∫
(m,c)
P (Y = 1|M = m˜(m), C = c, A = 0) fM |C=c,A=0(m)fC(c)dmdc
−P (Y0 = 1) , (10)
with a change-of-variables argument, where m˜(m) = m−1 log10 if m−1 log10 ≥
0, and m˜(m) is “below the limit of detection” otherwise. Therefore, we fit
the following logistic regression model for the probability of virologic control at
week 8 of ART interruption given M and C, using the Li et al. (2016) data
(Yi,Mi, Ci), i = 1, . . . , n, without curative treatment (A = 0):
logitpβ;m,c = logitP (Yi = 1|Mi = m,Ci = c, Ai = 0)
=
{
β0 + β1m+ β2c if m ≥ 0, i.e. above the limit of detection
β3 + β2c if m below the limit of detection.
(11)
Then, the indirect effect (10) can be estimated from from the ART interruption
data under no curative HIV drug (A = 0) by
n∑
i=1
(pβˆ;m˜(mi),ci − yi)/n,
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where βˆ is the result of the fit of model (11). After we have analyzed the data,
Table 1 will provide the results of this analysis. We will also include a 2 log10
and a 3 log10 shift. The interpretation of the estimates in Table 1 are the effects
of curative interventions that shift the distribution of the mediator and have no
direct effect on the time to viral rebound, or, in other words, the organic indirec
effects of curative HIV treatments that shift the distribution of the mediator.
Alternatively, if we would have on-ART biomarker measurements and in-
formation on C for study participants under the potential new curative HIV
treatment, say (m1,j , cj)
J
j=1 in a population similar to the population in Li
et al. (2016), but not necessarily ART interruption data under the potential
new curative HIV treatment, we could estimate the organic indirect effect by
J∑
i=j
pβˆ;m1,j ,cj/J −
n∑
i=1
yi/n.
If the pre-treatment characteristics are different in the two populations, match-
ing (see e.g. Rosenbaum (2017)) could be used on top, or Inverse Probability
of Treatment Weighting (see e.g. Robins et al. (2000); Herna´n et al. (2000)).
Alternatively, one could choose a distribution fC(c) of C of interest, fit a model
for the distribution of M0 given C (from the Li et al. (2016) data) and M1
given C (from the on-ART biomarker data under the potential new curative
HIV treatment (m1,j , cj)
J
j=1), and estimate the organic indirect effect in this
population by∫
(m,c)
pβˆ;m,c
(
fˆM |C=c,A=1(m)− fˆM |C=c,A=0(m)
)
fC(c)dmdc,
evaluating the integrals e.g. by simulating from the estimated distribution of
M given C under A = 1 and A = 0. If the distribution of C of interest is that
of the population in Li et al. (2016), the distribution of M0 doesn’t need to be
estimated, and one could estimate the organic indirect effect in this population
by
n∑
i=1
∫
m
pβˆ;m,ci fˆM |C=ci,A=1(m)dm/n−
n∑
i=1
yi/n.
In the above, we have assumed that the probability of virologic control
doesn’t depend on how far below the limit of detection a mediator value lies.
If a potential new curative HIV treatment also lowers the mediator further be-
low the limit of detection, the indirect effect of the potential new curative HIV
treatment could be larger than we predict above.
The confidence intervals were calculated by bootstrap using Efron’s per-
centile method (Van der Vaart (1998)), which leads to consistent coverage be-
cause of the Bootstrap Masters Theorem from Kosorok (2008).
The approach above can be carried out for many potential curative HIV
drugs. The most promising curative HIV drugs can then be tested in future
clinical trials which include ART interruption.
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6 Discussion
Both for natural direct and indirect effects and for the direct and indirect effects
proposed in Didelez et al. (2006), one needs to be able to set mediator to any
specific value. For “organic” direct and indirect effects, one only needs to be
able to affect the distribution of the mediator, and that is often what potential
new treatments will aim to accomplish. Organic direct and indirect effects as
introduced in Lok (2016) generalize natural direct and indirect effects.
To answer clinical questions, it is often useful to combine interventions on
the mediator with “no treatment”, rather than with “treatment”. Our new
definition of organic direct and indirect effects, which combines interventions
on the mediator with “no treatment”, no longer generalizes natural direct and
indirect effects; it is however closer to the original definition proposed by Baron
and Kenny (1986). The newly defined organic indirect effects can be estimated
without outcome data under treatment. As we illustrated in Section 5, this
is very useful for selecting potential new treatments with a promising indirect
effect for further evaluation in clinical trials. Often, a treatment A targets,
maybe through pathways, some patient characteristic or blood value, a potential
mediator M . If we have information on C, M1, M0, and Y0, (M0 and Y0 maybe
from historical data), we can estimate the organic indirect effect of the treatment
A = 1: the effect of an intervention that affects the distribution of the mediator
the way the treatment does, and that has no direct effect. This is the effect of
the treatment A = 1 mediated through M .
One of the lessons learned from the analyses in Section 5 is the importance
of collecting pre-treatment common causes of the mediator and the outcome
(“C”), if one wants to use outcome data under “no treatment” to estimate the
effect of a potential new treatment based on its effect on the mediator. Similarly,
data on pre-treatment common causes is needed in a randomized clinical trial
of a new treatment if one wants to estimate the direct and indirect (through the
mediator) effects on the outcome.
As is usually the case with mediation analysis, if the mediator studied is
just a marker for some underlying disease process, it can’t be expected that the
distribution of the outcome given M1 = m and given C is similar to the distri-
bution of the outcome given M0 = m and C, unless the treatment affects the
marker through its effect on this underlying disease process. Only if the media-
tor reflects the underlying disease process is the organic indirect effect relevant.
A famous counter-example is the effect of yellow fingers on lung cancer; “yellow
fingers” would constitute an irrelevant mediator, unless used as a measure of
smoking intensity. Bosch et al. (2013) illustrates that the meaning of media-
tion analysis is distorted when the interpretation of the potential mediator is
different under treatment and under no treatment. In this HIV study, IL-2 im-
proved the CD4 count, and in prior ART treatment trials, improved CD4 count
had been shown to be a predictor of better clinical outcomes. However, IL-2
did not show improved clinical outcomes in randomized clinical trials. Further
analyses showed that improved CD4 counts due to IL-2 were not predictive of
clinical benefit. Stated in terms of interventions, whether the mediator CD4
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count came about due to IL-2 had a different prognostic effect on the outcome
of interest than whether the mediator CD4 count came about naturally, which
shows that IL-2 is not an organic intervention, but which also shows that the
organic indirect effect mediated by the CD4 count is not that interesting for
IL-2. Another aspect that illustrates this is that the CD4 count values resulting
from IL-2 can be much higher than typically seen in any HIV-infected patient,
resulting in equation (4) conditioning on null events. Natural direct and indirect
effects are not defined in this situation, since they require common agreement on
“the closest possible world to this one” in which the mediator CD4 count under
“treatment” is set to its value under “no treatment”. This is a typical situation
where how the mediator is set to a specific value depends on the intervention
that sets it, since how the CD4 count came about (no treatment/ART/IL-2)
affects the prognostic value of the CD4 count. The take-home message from
this is that when carrying out causal mediation analysis for the selection of the
most promising treatments, mechanism of action and subject matter knowledge
are important considerations.
Since the Mediation Formula holds for organic direct and indirect effects,
many results for natural direct and indirect effects generalize to organic direct
and indirect effects. E.g., Valeri and VanderWeele (2013) shows how direct
and indirect effects can be estimated when there is measurement error. Valeri
and VanderWeele (2013) also shows that if there is measurement error in the
mediator, as is the case for the mediators in our illustrative HIV example, the
indirect effect is typically underestimated. It is an interesting topic for future
research to consider measurement error in the mediator when the mediator can
also be below the assay limit of detection.
Analogous to Lok (2016), the newly proposed organic direct and indirect
effects can also be estimated from observational data, provided that all con-
founders have been measured; see Web-appendix H. Incorporating post-treatment
common causes of the mediator and the outcome is an interesting topic for fu-
ture research; some preliminary results can be found in Lok (2017).
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A The Mediation Formula for organic direct and
indirect effects
In this Web-appendix, we prove the Mediation Formula for the newly proposed
organic direct and indirect effects.
Theorem (Organic direct and indirect effects: the Mediation Formula for ran-
domized data). Under randomized treatment, consistency, and the definition of
organic interventions, the following holds for an intervention I that is organic
with respect to C:
E (Y0,I=1)
=
∫
(m,c)
E [Y |M = m,C = c, A = 0] fM |C=c,A=1(m)fC(c)dmdc.
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Proof:
E (Y0,I=1) = E (E [Y0,I=1|M0,I=1, C])
=
∫
(m,c)
E [Y0,I=1|M0,I=1 = m,C = c] fM0,I=1|C=c(m)dmfC(c)dc
=
∫
(m,c)
E [Y0|M0 = m,C = c] fM1|C=c(m)dmfC(c)dc
=
∫
(m,c)
E [Y0|M0 = m,C = c, A = 0] fM1|C=c,A=1(m)dmfC(c)dc
=
∫
(m,c)
E [Y |M = m,C = c, A = 0] fM |C=c,A=1(m)fC(c)dmdc.
The second equation follows because of the definition of conditional expecta-
tions. The third equation follows because of the two parts of the definition of
organic interventions. The fourth equation follows because under randomized
treatment,
A⊥⊥ (Y0,M0) |C and A⊥⊥M1|C.
The last equation follows from the Consistency Assumption.
B New definition of organic direct and indirect
effects: the product method of Baron and
Kenny (1986): proof
In this Web-appendix, we show that the product method of Baron and Kenny
(1986) holds under linear models, regardless of whether there is an interaction
between treatment and the mediator in the outcome model.
Assumptions for product method.
M = α0 + α1C + α2A+ M ,
with M⊥⊥A|C, and
Y = β0 + β1C + β2A+ β3M + β4AM + Y ,
with E[Y |M,A,C] = 0.
Theorem (product method for new organic indirect effect). Under the
above assumptions for the product method, the newly proposed organic indirect
effect is equal to
E (Y0,I=1)− EY0 = β3α2.
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Proof:
E (Y0,I=1)− EY0
=
∫
(m,c)
E [Y |M = m,A = 0, C = c](
fM |A=1,C=c(m)− fM |A=0,C=c(m)
)
fC(c)dmdc
=
∫
(m,c)
(β0 + β1c+ β3m)
(
fM |A=1,C=c(m)− fM |A=0,C=c(m)
)
fC(c)dmdc
= β3
∫
(m,c)
m
(
fM |A=1,C=c(m)− fM |A=0,C=c(m)
)
fC(c)dmdc
+
∫
c
(β0 + β1c)
∫
m
(
fM |A=1,C=c(m)− fM |A=0,C=c(m)
)
dmdc
= β3
∫
(m,c)
mfM |A=0,C=c(m− α2)fC(c)dmdc
−β3
∫
(m,c)
mfM |A=0,C=c(m)fC(c)dmdc+ 0
= β3
∫
(m˜,c)
(m˜+ α2)fM |A=0,C=c(m˜)fC(c)dm˜ dc
−β3
∫
(m,c)
mfM |A=0,C=c(m)fC(c)dmdc
= β3α2.
For the first equality we used the Mediation Formula. For the fourth equality
we used that fM |A=1,C=c(m) = fM |A=0,C=c(m− α2). For the fifth equality we
substituted m˜ = m− α2. That finishes the proof.
C Usefulness of combining “no treatment” with
intervention on the mediator: mother-to-child
transmission of HIV/AIDS
HIV-infected mothers can transmit the HIV virus to their infants. The effect of
AZT treatment on mother-to-child transmission of HIV-1 is surprisingly large,
given the limited effect of AZT mono-therapy on HIV-1 RNA (DeGruttola et al.
(2001)). Less than 20% of the effect of AZT on mother to child transmission can
be explained through the effect of AZT on HIV-1 RNA (Sperling et al. (1996)).
What is the likely effect on mother-to-child transmission of a potential new
treatment that has the same effect on HIV-1 RNA as AZT but no “direct” effect
on mother to child transmission? In this case, the outcome Y is an indicator
“newborn baby is HIV-infected”. The mediator M is HIV-1 RNA. I is an
intervention that, without AZT, causes the distribution of HIV-1 RNA, M0,I=1,
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to be the same as under AZT; the potential new treatment. The quantity of
interest is then EY0,I=1 − EY0. Note: this quantity is different from the usual
indirect effect, since it combines an intervention I on the mediator with “no
treatment”, instead of with “treatment”.
The natural direct and indirect effect don’t have a lot of meaning in this
case, since the HIV viral load in the mother’s blood cannot be “set”. Once we
will be able to set the HIV viral load, we will set it to 0. Thus, for a treatment
like AZT, organic direct and indirect effects are more natural than their natural
counterparts.
Combining organic interventions I with “no treatment” provides useful in-
formation on what to expect from a treatment that:
1. Affects the HIV viral load in the mother’s blood the same way as AZT
does.
2. Has no direct effect on mother-to-child transmission.
D Uniqueness of organic direct and indirect ef-
fects
Definition: (common cause). X is not a common cause of mediator and
outcome given C if either equation (12) or equation (13) holds:
X⊥⊥M0 | C and X⊥⊥M1 | C (12)
or
X⊥⊥Y0 |M0, C. (13)
In graphical language: X is a common cause of the mediator and the outcome
if in a DAG that has C, X, M , and Y , there is an arrow from X to M , and
there is a direct arrow from X to Y . This definition of common cause is in line
with, for example, Pearl (2000).
Now, let IC be an intervention that is organic with respect to C and let
IC˜ be an intervention that is organic with respect to C˜. Assume that C is not
a common cause of the mediator and the outcome given C˜, and that C˜ is not
a common cause of the mediator and the outcome given C; hence there are
4 different cases, with either (12) or (13) holding for C and C˜, respectively.
Similar to Lok (2016), it can be shown that under any of those 4 different cases,
E
(
Y0,IC˜=1
)
=
∫
(m,c˜,c)
E
[
Y0 |M0 = m, C˜ = c˜, C = c
]
fM1|C˜=c˜,C=c(m)fC˜,C(c˜, c)dmdc˜ dc.
Because of symmetry, it follows that also
E
(
Y0,IC=1
)
=
∫
(m,c˜,c)
E
[
Y0 |M0 = m, C˜ = c˜, C = c
]
fM1|C˜=c˜,C=c(m)fC˜,C(c˜, c)dmdc˜ dc.
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But then, E
(
Y0,IC˜=1
)
= E
(
Y0,IC=1
)
. That finishes the proof.
E A weaker identifiability condition for natural
direct and indirect effects
Consider the situation where the mediator under treatment can be set to its
value without treatment, and there is consensus about the closest possible world
to this one where this can be accomplished. In this case, the natural direct and
indirect effects are well-defined. Now let M1,I=1 = M0; this is an intervention I
on the mediator. If all Ya,m “exist”, this intervention I is an organic intervention
if:
Y1,I=1|M1,I=1 = m,C = c ∼ Y1|M1 = m,C = c,
or equivalently, since in this particular example M1,I=1 = M0 and all Ya,m exist,
Y1,m|M0 = m,C = c ∼ Y1,m|M1 = m,C = c. (14)
Analogous to Lok (2016), this follows e.g. under the usual conditions for iden-
tification of natural direct and indirect effects. Then, the natural direct and
indirect effects are the same as the organic direct and indirect effects.
Still, equation (14) is a cross-worlds assumption, with Y1,m conditional on
M0. This is no surprise, since the definition of natural direct and indirect effects
relies on cross-worlds quantities. Still, the above relaxes the usual assumptions
for identification of natural direct and indirect effects.
F Indirect effects estimated from the effect of
the treatment on the mediator and outcome
data without treatment
For the situation where both the mediatior M and the outcome Y follow a
regression model, we have the product method from Baron and Kenny (1986),
see Web-appendix B.
In general, in equation (5), we derived that the new organic indirect effect
of a treatment is equal to∫
(m,c)
E [Y |M = m,C = c, A = 0] (fM |C=c,A=1(m)− fM |C=c,A=0(m)) fC(c)dmdc.
In this Web-appendix, we present some examples on how to use this formula
to estimate the new organic indirect effect. For example, Y without treatment
could be continuously distributed, and follow a regression model under no treat-
ment such as
Y = β0 + β1C + β2M + β3CM + Y ,
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with E[Y |M,C] = 0. Or, Y under no treatment could follow a logistic regres-
sion model such as
logit P(Y = 1|M = m,C = c,A = 0) = β0 + β1C + β2M + β3CM.
More generally, Y could be continuous or binary and follow a generalized linear
model such as
E [Y |M = m,C = c, A = 0] = g−1(β1C + β2M + β3CM), (15)
with g any link function. This includes both regression and logistic regression,
so we will work with (15) below.
An estimator for the new organic indirect effect that can always be used if
equation (15) holds is
n∑
i=1, person i treated
g−1(βˆ1ci + βˆ2mi + βˆ3cimi)
−
n∑
i=1, person i untreated
g−1(βˆ1ci + βˆ2mi + βˆ3cimi). (16)
The ingredients in this expression can easliy be estimated using most statistical
software packages. First, (15) is fitted using both mediator and outcome data
under no treatment, and then the mediator data under both no treatment and
under treatment can be plugged into (16).
Next, we present two specific examples besides the setting from Baron and
Kenny (1986). As a first specific example, if (15) holds under no treatment and
the mediator M is binary, the new organic indirect effect of a treatment is equal
to∫
(m,c)
E [Y |M = m,C = c, A = 0] (fM |C=c,A=1(m)− fM |C=c,A=0(m)) fC(c)dmdc
=
∫
c
g−1(β1c)(P (M = 0|C = c, A = 1)− P (M = 0|C = c, A = 0)) dc
+
∫
c
g−1(β1c+ β2 + β3c)(P (M = 1|C = c, A = 1)− P (M = 1|C = c, A = 0)) dc,
which under the usual regularity conditions can be consistently estimated by
n∑
i=1
g−1(βˆ1ci)(Pˆ (M = 0|C = ci, A = 1)− Pˆ (M = 0|C = ci, A = 0))
+
n∑
i=1
g−1(βˆ1ci + βˆ2 + βˆ3ci)(Pˆ (M = 1|C = ci, A = 1)− Pˆ (M = 1|C = ci, A = 0)).
Here, Pˆ (M = 1|C = ci, A = 1) and Pˆ (M = 1|C = ci, A = 0) can be estimated
using one’s favorite model for binary variables.
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As a second specific example, consider the situation where (15) holds under
no treatment and the mediator M is continuous and follows a regression model
M = α0 + α1C + α2A+ M ,
with M⊥⊥A|C. In this situation, the new organic indirect effect of a treatment
is equal to∫
(m,c)
g−1(β1c+ β2m+ β3cm)
(
fM |C=c,A=0(m− α2)− fM |C=c,A=0(m)
)
fC(c)dmdc
=
∫
(m,c)
g−1(β1c+ (β2 + β3c)(m˜+ α2))fM |C=c,A=0(m˜)fC(c)dmdc
−
∫
(m,c)
g−1(β1c+ (β2 + β3c)m)fM |C=c,A=0(m)fC(c)dmdc
=
∫
(m,c)
g−1(β1c+ (β2 + β3c)(m+ α2))fM |C=c,A=0(m)fC(c)dmdc
−
∫
(m,c)
g−1(β1c+ (β2 + β3c)m)fM |C=c,A=0(m)fC(c)dmdc,
where we used that fM |A=1,C=c(m) = fM |A=0,C=c(m− α2) and we introduced
m˜ = m − α2. Under the usual regularity conditions this can be consistently
estimated by e.g.
n∑
i=1, person i untreated
g−1(βˆ1ci + (βˆ2 + βˆ3ci)(mi + αˆ))− g−1(βˆ1ci + (βˆ2 + βˆ3ci)mi).
In our HIV application, we could consider a new treatment which, given the
pre-treatment common causes of the mediator, log HIV persistence, and the
outcome, time to rebound, shifts the distribution of the log HIV persistence
measure to the left by 1 log, or more generally, α logs. In that situation, as-
suming that (15) holds for the outcome, the indirect effect of the new treatment
mediated by the log HIV persistence measure is∫
(m,c)
g−1(β1c+ β2m+ β3cm)
(
fM |C=c,A=0(m− α)− fM |C=c,A=0(m)
)
fC(c)dmdc
=
∫
(m,c)
g−1(β1c+ (β2 + β3c)(m˜+ α))fM |C=c,A=0(m˜)fC(c)dmdc
−
∫
(m,c)
g−1(β1c+ (β2 + β3c)m)fM |C=c,A=0(m)fC(c)dmdc
=
∫
(m,c)
g−1(β1c+ (β2 + β3c)(m+ α))fM |C=c,A=0(m)fC(c)dmdc
−
∫
(m,c)
g−1(β1c+ (β2 + β3c)m)fM |C=c,A=0(m)fC(c)dmdc.
We can estimate this organic indirect effect of the new treatment mediated by
the log HIV persistence measure from 1) assuming a particular value of α, or
24
estimate α for a particular new treatment, and 2) use mediator and outcome
data under no treatment to fit (15). The estimated new organic indirect effect
of the new treatment mediated by the log HIV persistence measure equals
n∑
i=1, person i untreated
g−1(βˆ1ci + (βˆ2 + βˆ3ci)(mi +α))− g−1(βˆ1ci + (βˆ2 + βˆ3ci)mi).
G Multiplying the odds
In this Web-appedix, we show that if treatment increases the odds of a binary
variable M¯ being 1 by a factor F, then if P (M¯0 = 1) = p0 under no treatment,
P (M¯1 = 1) = Fp0/(1 − p0 + Fp0) under treatment. For F = 2, this means
thatP (M¯1 = 1) = 2p0/(1 + p0).
Write p1 = P (M¯1 = 1). Then if the odds of 1 increases by a factor F due to
treatment,
p1/(1− p1) = Fp0/(1− p0)
⇒ p1 = F (1− p1)p0/(1− p0)
⇒ p1(1 + Fp0/(1− p0)) = Fp0/(1− p0)
⇒ p1(1− p0 + Fp0)/(1− p0) = Fp0/(1− p0)
⇒ p1(1− p0 + Fp0) = Fp0
⇒ p1 = Fp0/(1− p0 + Fp0).
H Observational data
With observational data, the definition of organic direct and indirect effects
should not change. Here we show that an identification result holds for obser-
vational data similar to the identification result for randomized data, provided
that C has all common causes of the mediator and the outcome.
There may exist baseline covariates Z (beyond the common causes C of the
mediator and the outcome) that need to be included in the analysis in order to
eliminate confounding:
Assumption: (No Unmeasured Confounding).
A⊥⊥ (Y0,M0) | C,Z and A⊥⊥Y1 | C,Z and A⊥⊥M1 | C,Z.
Theorem: (Organic direct and indirect effects: the Mediation Formula for
observational data). Assume No Unmeasured Confounding, Consistency, inter-
vention I is organic with respect to C, and given C, Z is not a common cause
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of the mediator and the outcome (see Web-appendix D). Then
E (Y0,I=1)
=
∫
(m,c,z)
E [Y |M = m,C = c, Z = z,A = 0]
fM |C=c,Z=z,A=1(m)fC,Z(c, z)dmd(c, z).
The proof of this Mediation Formula is similar to the proofs in Web-appendix A
and in Lok (2016).
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